elminda Ltd. services

CNS drugs exhibit the lowest approval success rates due to multiple challenges such as lack of efficacy in early and advanced stages of development, Poor target selection / engagement, poor translation from pre-clinical models and disease heterogeneity. BNA may contribute in CNS research and drug development by adding new objective endpoints, assisting in understanding drug mechanism, identifying placebo effects, mapping cognitive functions, serving as a screening tool, identifying subtypes and treatment protocol success and failure likelihood prediction.

BNA™ leverage machine-learning, advanced algorithms, and large-population databases to provide a revolutionary new way to understand how the brain’s neural networks are activated and inform about brain function.